Utah Medical Products, Inc. Experiences Revision in Its Stock Evaluation Amid Market Resilience
Utah Medical Products, Inc., a microcap company in pharmaceuticals and biotechnology, has adjusted its valuation, now showing a P/E ratio of 18 and a dividend yield of 108.47%. Its year-to-date return of 12.35% significantly outperforms the S&P 500, indicating resilience. Compared to peers, Utah Medical appears to be a more stable investment option.
Utah Medical Products' (NASDAQ:UTMD) Conservative Accounting Might Explain Soft Earnings
Utah Medical Products' recent lackluster earnings report, despite appearing soft, might be attributable to conservative accounting practices and negative unusual items totaling US$1.4m. These one-off deductions suggest that the company's statutory profit could be understating its true earnings potential. Consequently, analysts anticipate a potentially improved financial performance in the upcoming year if these unusual expenses do not recur.
Utah Medical Products' (NASDAQ:UTMD) Conservative Accounting Might Explain Soft Earnings
Utah Medical Products' recent earnings report, despite appearing lackluster, is likely influenced by conservative accounting practices, specifically a US$1.4 million reduction due to unusual one-off items. Stockholders seemed unconcerned, suggesting underlying positive factors. If these unusual expenses do not recur, the company's profit is expected to be higher next year, indicating that its statutory profit may currently understate its true earning potential.
[DEF 14A] UTAH MEDICAL PRODUCTS INC Definitive Proxy Statement
Utah Medical Products, Inc. (UTMD) has filed a Definitive Proxy Statement (DEF 14A) for its annual meeting on May 1, 2026. Stockholders will vote on re-electing two directors, ratifying Haynie & Company as the independent auditor, and an advisory vote on executive compensation. The document details compensation, stock ownership, corporate governance, and audit information, highlighting CEO pay, employee stock options, and the company's financial performance history compared to market indices.
(UTMD) Price Dynamics and Execution-Aware Positioning
This article provides an analysis of Utah Medical Products Inc. (NASDAQ: UTMD), highlighting neutral near and mid-term readings but a positive long-term bias. It outlines several AI-generated trading strategies, including long, breakout, and short positions, along with risk management parameters. The analysis details support and resistance levels across different time horizons for informed trading decisions.
Top Analyst Reports for American Express, Intuitive Surgical & Shopify
Zacks Research Daily highlighted top analyst insights on 16 leading companies, focusing on American Express (AXP), Intuitive Surgical (ISRG), Shopify Inc. (SHOP), and Utah Medical Products, Inc. (UTMD). The reports detail each company's recent performance, growth drivers, and potential challenges, with American Express showing growth despite high costs, Intuitive Surgical excelling with its da Vinci system, and Shopify expanding its merchant base. The analysis also covers Utah Medical Products' strong balance sheet, along with brief mentions of other companies like Petróleo Brasileiro S.A. - Petrobras, Southern Copper Corp., and Agnico Eagle Mines Ltd.
UTMD PE Ratio & Valuation, Is UTMD Overvalued
Utah Medical Products Inc (UTMD) is currently in the Fair zone based on its forward PS ratio compared to its five-year average, suggesting it's fairly valued. The article details UTMD's Price-to-Book ratio, Free Cash Flow yield, and compares its P/S ratio to competitors, noting that its current P/S appears unsustainable given its revenue growth. The fair price of UTMD is calculated using a relative valuation method.
Utah Medical Products Stock: Steady Niche Player in Women's and Neonatal Healthcare with Reliable Di
Utah Medical Products (UTMD) is presented as a stable, niche player in the medical device sector, focusing on women's and neonatal healthcare. The company is valued by North American investors for its consistent dividend yield of around 2.2%, conservative growth profile, and resilience in a specialized market. Its financial stability, lean operations, and specialization in high-margin devices contribute to predictable cash flows, making it appealing for dividend-seeking and long-term investors.
Utah Medical Products Stock: Steady Niche Player in Women's and Neonatal Healthcare with Reliable Di
Utah Medical Products (NASDAQ: UTMD) is highlighted as a stable, niche player in the medical device sector, focusing on women's healthcare and neonatal care with consistent dividend appeal. The company's conservative growth profile, lean structure, and specialized product offerings contribute to its resilience and attraction for dividend-seeking investors. Its mid-cap status and low trading volume require cautious consideration for entry and exit but reward long-term holders.
UTAH MEDICAL PRODUCTS Cyclically Adjusted Book per Share: $3
This article from GuruFocus focuses on Utah Medical Products (UTMD) and its Cyclically Adjusted Book per Share, which was $32.42 as of September 2025. It explains the calculation of this metric, which averages the inflation-adjusted book value per share over the past 10 years, similar to Professor Robert Shiller's E10 concept. The article notes that UTMD has a GF Score of 81/100 and is considered "Fairly Valued" with 4 warning signs.
Utah Medical Products 2025 10-K: Revenue $38.5M, EPS $3.48
Utah Medical Products (UTMD) reported fiscal 2025 revenue of $38.52 million and diluted EPS of $3.48, a decrease from the previous year. The revenue decline was mainly due to lost OEM and China distributor orders, while EPS moderately benefited from share repurchases. Management anticipates stabilizing revenue in 2026 by securing new biopharma business and launching new products, with profitability expected to improve as amortization expenses ease after Q1.
Vanguard realignment leaves Utah Medical Products (UTMD) with 0% stake
The Vanguard Group has reported a 0% beneficial ownership stake in Utah Medical Products Inc. (UTMD) following an internal realignment effective January 12, 2026. This change, documented in an Amendment No. 2 to a Schedule 13G/A, signifies that Vanguard’s subsidiaries will now report their holdings separately, in accordance with SEC Release No. 34-39538. The filing clarifies that Vanguard no longer holds beneficial ownership over securities held by these disaggregated subsidiaries.
Utah Medical Products, Inc. Experiences Revision in Its Stock Evaluation Metrics
Utah Medical Products, Inc. has adjusted its stock valuation, now featuring a P/E ratio of 18 and a price-to-book value of 1.72. The company exhibits a high dividend yield of 108.47%, along with strong returns on capital and equity. These metrics position Utah Medical Products favorably against competitors within the Pharmaceuticals & Biotechnology sector.
Utah Medical Products Adjusts Valuation Grade Amid Strong Financial Metrics and High Dividend Yield
Utah Medical Products, Inc. has received a more favorable valuation grade due to strong financial metrics. These include a competitive P/E ratio of 18, a reasonable Price to Book Value of 1.72, and a high dividend yield of 108.47%. Despite operational challenges and a decline in operating profit over the past five years, the company maintains a low debt-to-equity ratio and high institutional holdings.
UTAH MEDICAL PRODUCTS Debt-to-EBITDA: 0.02 — Near Median
Utah Medical Products (UTMD) has a Debt-to-EBITDA ratio of 0.02 as of September 2025, which is consistent with its 10-year median and significantly lower than the Medical Devices & Instruments industry median of 1.44. This places UTMD in the top 2.4% of its industry for this metric, suggesting strong debt management. Despite its low Debt-to-EBITDA, GuruFocus has rated UTMD as "Fairly Valued" with a GF Score of 79/100, noting 4 warning signs that investors should consider in a full analysis.
Utah Medical’s Cash-Rich Model Is Carrying It Through A Sales Dip
Utah Medical Products, Inc. (UTMD) is navigating a sales decline through its strong cash reserves, high margins, and strategic capital returns like dividends and share buybacks. Despite facing challenges from lost OEM and distributor orders, the medical device manufacturer's resilience is supported by its cash position and shareholder-friendly policies. The company's future stock performance largely depends on its ability to replace lost sales volumes while maintaining its niche market quality and financial discipline.
Utah Medical Products (NASDAQ:UTMD) Stock Passes Above 200 Day Moving Average - Here's What Happened
Utah Medical Products (NASDAQ:UTMD) has surpassed its 200-day moving average, trading at $63.80 after reaching a high of $65.56. This comes as Weiss Ratings upgraded the stock from "sell" to "hold" and the company announced a quarterly dividend of $0.31 per share. Institutional investors have also increased their holdings in UTMD.
EBIT per share of Utah Medical Products, Inc. – SWB:UTM
This article provides the EBIT per share information for Utah Medical Products, Inc. (SWB:UTM) as listed on the Stuttgart Stock Exchange. The content appears to be a financial data page from TradingView, displaying key financial metrics for the company.
(UTMD) as a Liquidity Pulse for Institutional Tactics
This article analyzes Utah Medical Products Inc. (NASDAQ: UTMD) using AI models to provide institutional trading strategies. It highlights a positive near-term sentiment within a long-term strong context, despite mid-term weakness, and outlines specific position, momentum breakout, and risk hedging strategies with target prices and stop losses. The analysis also features multi-timeframe signal insights and an exceptional risk-reward setup.
Utah Medical Products Adjusts Valuation Amid Mixed Financial Performance and Strong Returns
Utah Medical Products, Inc. has seen a revised valuation grade from fair to attractive despite challenges like declining profits and negative financial performance in Q4 2025. The company maintains a competitive position with a P/E ratio of 16, high return on capital employed (35.70%), and significant institutional holding (79.23%). Although the stock returned 10.73% last year, profits decreased by 19.7%.
(UTMD) Risk Channels and Responsive Allocation
This report analyzes Utah Medical Products Inc. (NASDAQ: UTMD), highlighting a mid-channel oscillation pattern and a 23.9:1 risk-reward setup targeting a 6.9% gain. It provides institutional trading strategies for different risk profiles, including position trading, momentum breakout, and risk hedging. The analysis also includes multi-timeframe signal analysis, showing weak near-term and strong long-term sentiment for UTMD.
UTMD SEC Filings - Utah Med Prods 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Utah Medical Products (UTMD) SEC filings, including 10-K annual reports, 10-Q quarterly reports, and 8-K material event forms, accompanied by AI-generated summaries. It highlights the company's financial performance, operational details, and key corporate events such as dividend changes and director appointments. The article also includes a summary of UTMD's Q2 2025 results, noting decreased sales and gross profit but strong cash reserves and ongoing share repurchases.
(UTMD) Movement as an Input in Quant Signal Sets
This article provides an in-depth AI-generated analysis of Utah Medical Products Inc. (UTMD), focusing on its stock movement for quantitative signal sets. It presents key findings, institutional trading strategies tailored to different risk profiles, and a multi-timeframe signal analysis, indicating current neutral near-term readings and strong mid-term sentiment. The report also highlights elevated downside risk due to a lack of long-term support signals.
Electrosurgical Devices Market to Reach USD 10,220.04 Million by 2034, Growing at 6.34% CAGR | DelveInsight
The global electrosurgical devices market is projected to reach USD 10,220.04 million by 2034, growing at a CAGR of 6.34% from 2025. This growth is driven by increasing surgical volumes, the rising prevalence of chronic diseases, and the growing adoption of minimally invasive surgery. North America currently leads the market, while Asia-Pacific is expected to be the fastest-growing region, with key players like Medtronic and Johnson & Johnson dominating the competitive landscape.
Utah Medical Products (STU:UTM) PensionAndRetirementBenefit : €0.00 Mil (As of Sep. 2025)
This article provides financial data for Utah Medical Products (STU:UTM), specifically focusing on its PensionAndRetirementBenefit, which is reported as €0.00 million as of September 2025. It explains what PensionAndRetirementBenefit represents and offers historical data trends, accessible to premium members, for both annual and quarterly periods. The article also includes a business description of Utah Medical Products and lists comparable companies.
Utah Medical Products (STU:UTM) Other Stockholders Equity : €0.00 Mil (As of Sep. 2025)
This article provides financial data for Utah Medical Products (STU:UTM), specifically focusing on its "Other Stockholders Equity" as of September 2025, which stood at €0.00 million. It highlights the quarterly and annual trends of this metric, noting recent increases in quarterly figures and an increase in annual figures from December 2023 to December 2024 after a previous decline. The content also offers historical data, charts, and defines "Other Stockholders Equity" within the context of a company's total equity.
Utah Medical Products (STU:UTM) Sale Of Property, Plant, Eq
This article reports that Utah Medical Products (STU:UTM) had €0.00 million in sales from property, plant, and equipment for the trailing twelve months (TTM) ended September 2025 as well as for the quarter ended September 2025. This figure indicates no gain from the sale of such assets during these periods. The report also includes historical data and charts on these sales, which can be accessed by premium members of GuruFocus.com.
Utah Medical Products (STU:UTM) Notes Receivable : €0.00 Mil (As of Sep. 2025)
This article provides financial data for Utah Medical Products (STU:UTM), specifically focusing on its Notes Receivable. As of September 2025, the company's Notes Receivable stood at €0.00 million. The report includes historical data and defines Notes Receivable as an unconditional promise to receive a definite sum of money at a future date within one year.
Utah Medical Products (STU:UTM) Days Sales Outstanding : 34.51 (As of Sep. 2025)
This article provides an analysis of Utah Medical Products' (STU:UTM) Days Sales Outstanding (DSO) as of September 2025, which stands at 34.51. It details the calculation of DSO, presents historical data and charts, and compares the company's performance to industry peers. The DSO of 34.51 is better than 87.16% of companies in the Medical Devices & Instruments industry, indicating efficient management of accounts receivable.
Utah Medical Products (STU:UTM) YoY Rev. per Sh. Growth : 0.50% (As of Sep. 2025)
Utah Medical Products (STU:UTM) reported a Year-over-Year Revenue per Share Growth of 0.50% as of September 2025, with revenue per share for the quarter ending September 2025 at €2.61. The article provides historical data charts for both annual and quarterly YoY Rev. per Sh. Growth and details the calculation methodology. It also lists related financial terms, a business description, and comparable companies in the Medical Devices & Instruments industry.
Utah Medical Products (STU:UTM) Cash Conversion Cycle : 196.92 (As of Sep. 2025)
This article details Utah Medical Products' (STU:UTM) Cash Conversion Cycle (CCC), reporting it as 196.92 as of September 2025. It explains that CCC is calculated from Days Sales Outstanding, Days Inventory, and Days Payable, and provides historical data and competitive comparisons for the Medical Devices & Instruments industry. The article emphasizes that a lower CCC generally indicates better management effectiveness.
Utah Medical Products (STU:UTM) ROIC % : 23.16% (As of Sep. 2025)
Utah Medical Products (STU:UTM) reported an annualized Return on Invested Capital (ROIC %) of 23.16% for the quarter ending September 2025, significantly higher than its WACC of 8.88%. This indicates the company is generating excess returns on its investments. The article provides historical ROIC % data and detailed calculations for both annual and quarterly figures.
Utah Medical Products (NASDAQ:UTMD) Stock Price Passes Above 200 Day Moving Average - What's Next?
Utah Medical Products (NASDAQ:UTMD) stock recently broke above its 200-day moving average, trading as high as $68.71. Despite this technical breakout, analysts maintain a "Sell" rating for the stock. However, the company demonstrates solid fundamentals with a 29.3% net margin, a market cap of $217M, and a P/E of 19.49, along with a declared quarterly dividend.
Utah Medical's Q4 Earnings Hurt by OEM Decline, Fall Y/Y
Utah Medical Products (UTMD) experienced a decline in its fourth-quarter and full-year 2025 earnings and revenue, primarily due to a significant drop in OEM sales and U.S. non-Filshie device sales. Despite these struggles, the company's share price has outpaced the S&P 500, and it maintains a strong cash position with no debt. Management expects continued challenges from the absence of sales to PendoTECH and its China distributor but plans to drive recovery through new products and organic growth.
Utah Medical's Q4 earnings hurt by OEM decline, fall y/y
Utah Medical Products (UTMD) reported lower Q4 earnings and revenue compared to the previous year, with diluted EPS falling to $0.80 from $0.94. The decline was primarily attributed to a drop in original equipment manufacturer (OEM) sales, despite a slight increase in core products revenue. Management noted the impact of continued inflationary pressures and changing customer inventory practices on profitability.
Liquidity Mapping Around (UTMD) Price Events
The article provides a detailed analysis of Utah Medical Products Inc. (UTMD) based on AI-generated signals, highlighting a strong near-term sentiment but neutral mid and long-term outlook. It identifies key resistance and support levels, presenting specific institutional trading strategies for various risk profiles, including long, breakout, and short setups. The analysis emphasizes a high risk-reward short setup with significant downside target against minimal risk.
Utah Medical Products' (NASDAQ:UTMD) Dividend Will Be $0.31
Utah Medical Products (NASDAQ:UTMD) is set to distribute a dividend of $0.31 per share on April 3rd, resulting in a 2.0% dividend yield. The company's dividends are well-covered by both cash flow and earnings, with projected earnings per share growth of 3.7% over the next year. Utah Medical Products boasts a stable dividend payment history over the last decade, making it an attractive option for income investors, despite limited dividend growth prospects.
Utah Medical Products Is Quietly Crushing It – But Is UTMD Stock Still Worth the Hype?
Utah Medical Products (UTMD) is a medical device company specializing in women's health, neonatal care, and surgery, operating profitably under Wall Street's radar. The article explores whether this small-cap, niche player offers a valuable investment opportunity for those seeking steady, fundamentals-driven growth rather than speculative "meme stock" returns. It highlights the company's consistent profitability, sticky demand in its specialized markets, and long-term compounding potential, contrasting it with high-growth, cash-burning companies.
Utah Medical's Q4 earnings hurt by OEM decline, fall y/y
Utah Medical Products (NASDAQ:UTMD) reported a decline in its Q4 earnings year-over-year, primarily attributed to a significant drop in its OEM sales. Excluding the OEM segment, the company's Q4 revenue saw a modest increase of 0.6% compared to the previous year. Despite the overall earnings dip, Utah Medical Products continues to operate debt-free.
Utah Medical Products, Inc. (NASDAQ:UTMD) Announces Quarterly Dividend of $0.31
Utah Medical Products, Inc. (NASDAQ:UTMD) has declared a quarterly dividend of $0.31 per share, payable on April 3rd to shareholders of record by March 17th. This dividend represents an annualized yield of 2.0%. The company has consistently increased its dividend for the past three consecutive years, although its average dividend growth over this period is reported as flat at 0.0%.
Why (UTMD) Price Action Is Critical for Tactical Trading
This article analyzes Utah Medical Products Inc. (UTMD) stock, highlighting a strong near-term sentiment with a neutral mid and long-term outlook. It identifies a significant risk-reward short setup and outlines three distinct AI-generated trading strategies: Position Trading, Momentum Breakout, and Risk Hedging, tailored for different risk profiles. The analysis emphasizes the importance of price action for tactical trading and provides support and resistance levels across various time horizons.
Utah Medical Products raises quarterly dividend by 1.6% to $0.31
Utah Medical Products (NASDAQ:UTMD) announced a 1.6% increase in its quarterly cash dividend to $0.31 per share, payable on April 3, 2026. The company, which specializes in healthcare products for women and babies, boasts a 2.0% dividend yield and has maintained payments for 22 consecutive years. This news follows the recent appointment of Kevin C. Timken to its Board of Directors, signaling strategic adjustments and efforts to enhance shareholder value.
Utah Medical Products raises quarterly dividend by 1.6% to $0.31
Utah Medical Products (NASDAQ:UTMD) has announced a 1.6% increase in its quarterly cash dividend to $0.31 per share, payable on April 3, 2026. The company, which specializes in healthcare products for women and babies, offers a 2.0% dividend yield and has maintained payments for 22 consecutive years. This news follows the appointment of Kevin C. Timken to its Board of Directors, reinforcing strategic adjustments aimed at enhancing governance and shareholder value.
Utah Medical Products Keeps Quarterly Dividend at $0.31 per Share, Payable April 3 to Holders of Record March 17
Utah Medical Products (UTMD) has announced that it will maintain its quarterly dividend at $0.31 per share. The dividend is scheduled to be paid on April 3 to shareholders who are on record as of March 17. The company specializes in medical devices for critical care and women's health.
Utah Medical's Q4 Earnings Hurt by OEM Decline, Fall Y/Y
Utah Medical Products (UTMD) reported a decline in Q4 2025 earnings and revenues, with EPS dropping 6.3% and revenues falling 1.2% year-over-year. The decrease was primarily driven by softness in U.S. sales of non-Filshie medical devices and a significant 31.5% drop in OEM sales, partially offset by an increase in OUS sales due to favorable foreign exchange rates. Despite the revenue decline, the company maintained a strong gross profit margin and ended the year with $85.8 million in cash and no debt, continuing share repurchases and dividends.
Utah Medical's Q4 Earnings Hurt by OEM Decline, Fall Y/Y
Utah Medical Products, Inc. (UTMD) reported a decline in Q4 2025 earnings and revenues, with EPS falling 6.3% and revenues down 1.2% year-over-year. The decrease was primarily attributed to soft U.S. sales of non-Filshie devices and a significant 31.5% drop in OEM sales, despite growth in U.S. Filshie device sales and a modest benefit from favorable foreign exchange rates in OUS sales. The company's full-year 2025 sales also decreased by 5.8%, and management expects continued challenges but plans to offset losses with new products and organic growth.
Utah Medical Products raises quarterly dividend by 1.6% to $0.31
Utah Medical Products (NASDAQ:UTMD) has announced a 1.6% increase in its quarterly cash dividend to $0.31 per share. The company, which specializes in healthcare products for women and babies, will pay the dividend on April 3, 2026, to shareholders of record on March 17, 2026. UTMD boasts a "GREAT" financial health score, a 2.0% dividend yield, and a 22-year history of consecutive dividend payments.
Dividend rises 1.6% at Utah Medical, now $0.31 a share
Utah Medical Products (Nasdaq: UTMD) announced a quarterly cash dividend of $0.31 per share, payable on April 3, 2026, to shareholders of record as of March 17, 2026. This dividend represents a 1.6% increase compared to the same quarter last year. The company specializes in developing and marketing medical devices for women and babies, distributing its products in over 100 countries.
Utah Medical's Q4 Earnings Hurt by OEM Decline, Fall Y/Y
Utah Medical Products (UTMD) recently reported Q4 2025 earnings per share of 80.2 cents, a 6.3% decrease year-over-year, and revenues of $9 million, down 1.2% from the prior year. The decline was primarily attributed to a significant drop in OEM sales and weak domestic U.S. sales of non-Filshie devices, despite growth in U.S. Filshie sales and a slight boost from favorable foreign exchange rates in international markets. The company managed to maintain a strong gross profit margin through cost containment efforts, but overall profitability was impacted by higher operating expenses and ongoing cost pressures.
Utah Medical Products Inc. (UTMD) Releases Q4 2025 Earnings: Revenue Down, Net Income and Operating Cash Flow Up
Utah Medical Products Inc. (UTMD) reported mixed Q4 2025 earnings with revenue declining by 1.41% year-over-year to $9.04 million, yet net income increased by 7.03% to $3.11 million. The company also saw a significant increase in operating cash flow by 32.04% to $3.88 million, maintaining a strong cash position despite a drop in operating profit. Institutional investor activity also saw a mix of additions and reductions in UTMD shares during Q3 2025.
